Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.38 |
| ▸ | TTK | P33981 | 4/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27196867 | 0.83 | TTK (0.55) | CDK2TTKCCNA2AURKAAURKB | |
| SCHEMBL27196893 | 0.83 | KDM4E (0.43) | CDK2CCNE1MAPK1PRKD1PRKD2 | |
| SCHEMBL29776381 | 0.81 | PIK3CA (0.38) | CDK2CCNE1MAPK1MAPK3CCNT1 | |
| SCHEMBL29776251 | 0.81 | LRRK2 (0.41) | CDK2CCNE1MAPK1MAPK3CCNT1 | |
| SCHEMBL24605435 | 0.81 | LRRK2 (0.41) | CDK2CCNE1MAPK1MAPK3CCNT1 | |
| SCHEMBL24605599 | 0.81 | PIK3CA (0.38) | CDK2CCNE1MAPK1MAPK3CCNT1 | |
| SCHEMBL29776233 | 0.81 | MAPK1 (0.44) | CDK2CCNE1MAPK1CCNT1PRKD1 | |
| SCHEMBL24605550 | 0.81 | MAPK1 (0.44) | CDK2CCNE1MAPK1CCNT1PRKD1 | |
| SCHEMBL27197260 | 0.80 | LRRK2 (0.46) | CDK2CCNE1MAPK1MAPK3CCNT1 | |
| SCHEMBL30595664 | 0.79 | SSTR3 (0.45) | CDK2CCNE1MAPK1TTKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | claimed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | claimed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | claimed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | CDK2 69/4885CCNE1 234/4885MAPK1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.